16 pharmaceutical stocks surveyed by institutions (with list)

In the past 5 trading days (November 4 to November 10), more than 100 companies in the two cities have been investigated by institutions, including 16 stocks in the pharmaceutical and biological industry, and 5 pharmaceutical stocks have been investigated by more than 20 institutions
。 Among them, Zhifei Biotechnology has attracted much attention and has been surveyed by 164 institutions, including many large institutions such as Wells Fargo Fund, CSC, Huatai Berui, Guotai Junan, Taikang Asset, Haitong Securities, Xingquan Fund, Huatai Baoxing, Donghai Fund, Centennial Insurance Assets, Xingyin Wealth Management, Golden Pine Xusong Investment and so on
.
The survey mainly focuses on the company's performance and operation in the first three quarters of this year, the progress of vaccine research and development, and the layout plan of HPV vaccine
.
Zhifei Biotech said in the survey that in the first three quarters of this year, the company's business development momentum was good, achieving operating income of 27.
823 billion yuan, a year-on-year increase of 27.
46%.

Among them, in the third quarter, the company achieved operating income of 9.
470 billion yuan and net profit of 1.
878 billion yuan
.
Eliminating cervical cancer is the common vision of all mankind, in recent years, China has been actively strengthening the scientific publicity of HPV vaccination, promoting the pilot work of HPV vaccine, and increasing the number
of HPV vaccination in China.
The Global Strategy for Accelerating the Elimination of Cervical Cancer released by China also reflects the strong demand for the domestic HPV vaccine market
.
Zhifei Biotech said that thanks to the vast space brought by the Chinese market and the recognition gained by 20 years of deep cultivation in the industry, the company believes that it can continuously achieve new breakthroughs
in market expansion under the catalyst of industry development opportunities.
Zhifei Biotech is a partner of Merck Chinese mainland and continues to work closely
with Merck in product import, promotion and sales.
In August this year, the nine-valent HPV vaccine officially landed to further enrich the product choices of women of appropriate age in China, effectively covering the two peak age groups of HPV infection to better meet the vaccination needs
of the public.
The company will continue to deepen cooperation with Merck to increase the supply of HPV
vaccines.
At the same time, the company will further optimize and refine the marketing network, promote the sinking of vaccines to vaccination sites at provincial, municipal and county levels across the country, and improve the accessibility of
vaccines in grassroots areas and remote areas.
In addition, Kain Technology and Yiqiao Shenzhou were investigated by 71 and 69 institutions respectively, and the number of institutions investigated by Price and Mabwell was also more than
30.
In terms of the number of institutional surveys, Guilin Sanjin has received institutional surveys as many as 2 times, and 15 other pharmaceutical companies such as Lizhu Group, Weili Medical, and Fujilai have all received 1 survey
.
From the perspective of the subdivisions that have attracted much attention from institutions, the participation of institutions in subdivided fields such as vaccines, traditional Chinese medicine, and medical devices is relatively high
.
Among them, the traditional Chinese medicine stocks surveyed by the institution include China Resources Sanjiu, Baiyunshan, Yiqiao Shenzhou, etc.
, and the medical device stocks include Weili Medical and Davy Medical
.
The industry believes that the prosperity of these subdivisions investigated by institutions is relatively high
.
Among them, traditional Chinese medicine is strongly supported by top-level policies such as the 14th Five-Year Plan, and in recent years, policies including encouraging the development of
talents in proprietary Chinese medicines, innovation in traditional Chinese medicines, medical insurance payment and other aspects have been issued one after another, and local favorable policies have also continued to be introduced.
Medical devices are also encouraged by policies, including domestic substitution, graded diagnosis and treatment, and encouraging innovation, which is expected to accelerate the localization process, and leading enterprises will embrace opportunities
.
From the performance of the third quarter, many surveyed pharmaceutical stocks have also achieved good results, and have achieved both growth in revenue and net profit
.
For example, China Resources achieved operating income of 12.
111 billion yuan in the third quarter, up 7.
53% year-on-year, and net profit attributable to owners was 1.
952 billion yuan, up 11.
17% year-on-year; Lizhu Group achieved a total operating income of RMB9.
488 billion, up 1.
27% year-on-year, and net profit attributable to its parent of RMB1.
507 billion, up 3.
72% year-on-year; Weili Medical achieved a total operating income of 1.
004 billion yuan, a year-on-year increase of 31.
29%, and a net profit attributable to the parent of 138 million yuan, a year-on-year increase of 68.
18%.

List of pharmaceutical and biological stocks that have been investigated by institutions in the past 5 days Data source: Securities Times Data treasure Chart: Pharmaceutical Network Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.